| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.9 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.9 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.9 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | -0.0065 | 0.9 |
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | 0.0086 | 0.9 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | -0.0067 | 0.9 |
| mRNA | Sunitinib | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | GW 441756 | GDSC1000 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | Gefitinib | FIMM | pan-cancer | AAC | 0.028 | 0.9 |